Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ENTA vs OMER: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OMER Captures Overall Composite Edge (54.1 HOLD vs 46.2 HOLD), While ENTA Leads 3–2 on Growth & Valuation Pillars

OMER Overall Winner 6-Pillar Tally: ENTA 3 – 2 OMER (1 Tie) Matrix Metrics: ENTA 3 – 7 OMER

As of Nov 16, 2026, Omeros Corporation (OMER) captures the overall head-to-head institutional edge over Enanta Pharmaceuticals, Inc (ENTA) on higher Unified Composite conviction (54.1/100 HOLD vs. 46.2/100 HOLD) after splitting the core matrix 7–3 (led by Growth & Scale, Options & Positioning), while ENTA wins 3–2 across the 6-pillar growth and valuation breakdown. ENTA trades at $10.79 (44.0x Forward P/E, -90.0% operating margin) versus OMER at $17.18 (75.8x Forward P/E, -189.5% operating margin).

  • Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (54.1/100 HOLD vs. ENTA 46.2/100 HOLD) and 1.81β · 54% Vol risk profile, whereas ENTA leads top-line expansion (-21.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ENTA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0); meanwhile OMER trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENTA vs OMER
ENTA NASDAQ
Enanta Pharmaceuticals, Inc
Pharmaceutical Preparations
$10.79
-1.82% 1D
Market Cap $326.2M
TTM Revenue $65M
Forward P/E 44.0x
Beta / 30D Vol 0.89β · 58% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $11.18 · SMA50: $11.88
OMER NASDAQ Head-to-Head Winner
Omeros Corporation
Pharmaceutical Preparations
$17.18
-1.8% 1D
Market Cap $1.3B
TTM Revenue $27M
Forward P/E 75.8x
Beta / 30D Vol 1.81β · 54% Vol
Unified Composite Score
54.1 / 100 HOLD
Tech 44.0 Fund 55.0 Flow 74.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $17.47 · SMA50: $18.23

6-Pillar Scorecard Institutional Category Breakdown (ENTA 3 – 2 OMER)

Columns: Metric · ENTA · OMER
1. Valuation Multiples ENTA
Forward P/E 44.0x 75.8x
Trailing P/E 44.0x 14.9x
PEG Ratio N/M 0.81x
EV / Revenue 5.3x 51.9x
2. Growth & Scale OMER
Revenue Growth (YoY) -21.6% +14.9%
Earnings Growth (YoY) -66.2% +0.0%
TTM Revenue (USD) $65M $27M
Market Cap $326.2M $1.3B
3. Profitability & Quality ENTA
Gross Margin 100.0% 38.3%
Operating Margin -90.0% -189.5%
Net Profit Margin -96.9% 324.9%
Return on Equity (ROE) -70.1% -576.3%
4. Balance Sheet & Cash Flow ENTA
Cash Generation (TTM) -$37M -$48M
Cash Flow Margin -56.6% N/A
Net Cash / Leverage $22M Net Debt (0.55x D/E) $96M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OMER
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 78.7% (11th %ile) 147.9% (99th %ile)
Put/Call OI Skew 0.31x (Call-Skewed) 0.09x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENTA (3) vs OMER (7)
Institutional Metric ENTA OMER Criterion Row Edge
Market Capitalization
Scale
$326.2M $1.3B Larger Scale OMER
Trailing P/E Ratio
Valuation
44.0x 14.9x Lower Multiple OMER
Forward P/E Ratio
Valuation
44.0x 75.8x Lower Multiple ENTA
Revenue Growth (YoY)
Growth
-21.6% +14.9% Higher Growth OMER
Operating Margin (TTM)
Profitability
-90.0% -189.5% Higher Margin ENTA
Net Profit Margin
Profitability
-96.9% 324.9% Higher Margin OMER
Return on Equity (ROE)
Capital Efficiency
-70.1% -576.3% Higher ROE ENTA
52-Week Range Position
Momentum
10% ($10–$17) 73% ($6–$21) Stronger Trend OMER
Beta / 30D Volatility
Risk Regime
0.89β · 58% Vol 1.81β · 54% Vol Lower Realized Risk OMER
Unified Institutional Score
Composite Signal
46.2 / 100 (HOLD) 54.1 / 100 (HOLD) Higher Composite OMER
Trailing 12M Revenue (USD)
Operating Scale
$65M $27M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 38.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.3x EV/Rev 0.81x PEG · 51.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$37M ($22M Net Debt (0.55x D/E)) -$48M ($96M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OMER +8.81 pp
ENTA: -2.79% · OMER: +6.02%
3M Horizon OMER +18.78 pp
ENTA: -18.87% · OMER: -0.09%
6M Horizon OMER +66.57 pp
ENTA: -19.78% · OMER: +46.79%
1Y Horizon OMER +181.43 pp
ENTA: -7.94% · OMER: +173.49%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ENTA Revenue OMER Revenue ENTA Op. Margin OMER Op. Margin Margin Leader
FY2018 $210M $30M 42.7% -375.7% ENTA
FY2019 $210M $110M 17.9% -130.6% ENTA
FY2020 $120M $70M -34.0% -212.6% ENTA
FY2021 $100M N/A -112.9% N/A ENTA
FY2022 $90M N/A -143.7% N/A ENTA
FY2023 $80M N/A -173.2% N/A ENTA
FY2024 $70M N/A -179.9% N/A ENTA
FY2025 $70M N/A -130.7% N/A ENTA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENTA BREAKDOWN
95d in phase · OBV NEUTRAL
Current IV 78.7%
IV Percentile 11th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ENTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OMER CONSOLIDATION
39d in phase · OBV DISTRIBUTION
Current IV 147.9%
IV Percentile 99th %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact OMER Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $326.2M market capitalization and -90.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OMER Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -189.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENTA vs OMER Key Questions & Quantitative Answers

As of Nov 16, 2026, Omeros Corporation (OMER) captures the overall head-to-head institutional edge over Enanta Pharmaceuticals, Inc (ENTA) on higher Unified Composite conviction (54.1/100 HOLD vs. 46.2/100 HOLD) after splitting the core matrix 7–3 (led by Growth & Scale, Options & Positioning), while ENTA wins 3–2 across the 6-pillar growth and valuation breakdown. ENTA trades at $10.79 (44.0x Forward P/E, -90.0% operating margin) versus OMER at $17.18 (75.8x Forward P/E, -189.5% operating margin). Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (54.1/100 HOLD vs. ENTA 46.2/100 HOLD) and 1.81β · 54% Vol risk profile, whereas ENTA leads top-line expansion (-21.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ENTA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0); meanwhile OMER trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OMER leads the Growth & Scale pillar: ENTA posts -21.6% YoY revenue growth and -66.2% YoY earnings growth on $65M TTM revenue (100.0% gross margin, -90.0% operating margin), compared with OMER at +14.9% YoY revenue growth and +0.0% YoY earnings growth on $27M TTM revenue (38.3% gross margin, -189.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ENTA cumulative revenue shifted -66.7% while OMER shifted +133.3%. In operating R&D and SG&A reinvestment, ENTA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OMER.

ENTA screens cheaper on headline valuation multiples. ENTA trades at 44.0x Forward P/E, 44.0x Trailing P/E, N/M PEG, and 5.3x EV/Revenue (-56.6% FCF margin), whereas OMER trades at 75.8x Forward P/E, 14.9x Trailing P/E, 0.81x PEG, and 51.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTA (-70.1% ROE) versus OMER (-576.3% ROE) capital efficiency.

In options market volatility and institutional positioning, ENTA carries 78.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 58% Vol realized risk). By comparison, OMER carries 147.9% implied volatility (99th %ile, Extreme (>80th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.81β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.